These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25548093)

  • 21. Adding fuel to the fire: immunogenic intensification.
    O'Sullivan Coyne G; Gulley JL
    Hum Vaccin Immunother; 2014; 10(11):3306-12. PubMed ID: 25483630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CIMT 2009: report on the seventh annual meeting of the association for immunotherapy of cancer. June 3-5, Mainz, Germany.
    Diken M; Widenmeyer M; Gouttefangeas C; Welters MJ; Britten CM
    Cancer Immunol Immunother; 2010 Sep; 59(9):1417-23. PubMed ID: 19771427
    [No Abstract]   [Full Text] [Related]  

  • 23. New checkpoint inhibitors ride the immunotherapy tsunami.
    Mullard A
    Nat Rev Drug Discov; 2013 Jul; 12(7):489-92. PubMed ID: 23812256
    [No Abstract]   [Full Text] [Related]  

  • 24. Breakthrough of the year 2013. Cancer immunotherapy.
    Couzin-Frankel J
    Science; 2013 Dec; 342(6165):1432-3. PubMed ID: 24357284
    [No Abstract]   [Full Text] [Related]  

  • 25. Cancer Immunotherapy Researchers Focus on Refining Checkpoint Blockade Therapies.
    Jacob JA
    JAMA; 2015 Nov; 314(20):2117-9. PubMed ID: 26599172
    [No Abstract]   [Full Text] [Related]  

  • 26. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients.
    Kitano S; Tsuji T; Liu C; Hirschhorn-Cymerman D; Kyi C; Mu Z; Allison JP; Gnjatic S; Yuan JD; Wolchok JD
    Cancer Immunol Res; 2013 Oct; 1(4):235-44. PubMed ID: 24396833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate cancer immunotherapy.
    May KF; Gulley JL; Drake CG; Dranoff G; Kantoff PW
    Clin Cancer Res; 2011 Aug; 17(16):5233-8. PubMed ID: 21700764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coinhibitory Pathways in Immunotherapy for Cancer.
    Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
    Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CIMT 2024: Report on the 21st Annual Meeting of the Association for Cancer Immunotherapy.
    Ahrberg Y; Dallmann J; Freitag J; Hassan A; Jung C; Kiefer J; Muralidharan AM; Peter M; Beck JD
    Hum Vaccin Immunother; 2024 Dec; 20(1):2381925. PubMed ID: 39043196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Melanoma immunotherapy: historical precedents, recent successes and future prospects.
    Raaijmakers MI; Rozati S; Goldinger SM; Widmer DS; Dummer R; Levesque MP
    Immunotherapy; 2013 Feb; 5(2):169-82. PubMed ID: 23413908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.
    Hopkins AC; Yarchoan M; Durham JN; Yusko EC; Rytlewski JA; Robins HS; Laheru DA; Le DT; Lutz ER; Jaffee EM
    JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cocktails for cancer with a measure of immunotherapy.
    Ledford H
    Nature; 2016 Apr; 532(7598):162-4. PubMed ID: 27075078
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment.
    Lisi L; Lacal PM; Martire M; Navarra P; Graziani G
    Pharmacol Res; 2022 Jan; 175():105997. PubMed ID: 34826600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations.
    Tran E; Robbins PF; Rosenberg SA
    Nat Immunol; 2017 Feb; 18(3):255-262. PubMed ID: 28198830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy for malignant melanoma.
    Zeiser R; Schnitzler M; Andrlova H; Hellige T; Meiss F
    Curr Stem Cell Res Ther; 2012 May; 7(3):217-28. PubMed ID: 22329580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Regulatory T cells in cancer immunotherapy].
    Nishikawa H
    Rinsho Ketsueki; 2014 Oct; 55(10):2183-9. PubMed ID: 25297785
    [No Abstract]   [Full Text] [Related]  

  • 38. Cancer immunotherapy 2005: Mainz, Germany, 12-13 May 2005.
    Britten CM; Gouttefangeas C; Kreiter S
    Cancer Immunol Immunother; 2006 Apr; 55(4):475-80. PubMed ID: 16193336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting neoantigens for cancer immunotherapy.
    Lu YC; Robbins PF
    Int Immunol; 2016 Jul; 28(7):365-70. PubMed ID: 27208041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 8th Annual Canadian Cancer Immunotherapy Consortium (CCIC) Symposium 2015--May 20-22, Vancouver, Canada.
    Boudreau JE; Wouters MC; Krawczyk CM
    Cancer Immunol Immunother; 2016 Feb; 65(2):235-41. PubMed ID: 26759005
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.